they are essentially the same medication, with Monjourno being the marketed brand name.
In 2022, the FDA announced there was a shortage of the brand-name medications, which allowed compounding pharmacies to make generic semaglutide, the main active ingredient in the weight-loss drugs
Selected Research References Seiwerth S, Sikiric P, Rucman R, et al
Start your intake How Graves' Disease Affects Metabolism and Weight Graves' disease occurs when the immune system attacks the thyroid gland, causing it to produce excess thyroid hormone
Unexpected Symptoms New or persistent symptoms should be discussed with the provider rather than assumed to be a normal part of treatment
The final approved dosing schedule hasnt been established since the medication awaits regulatory clearance